Ironwood Pharmaceuticals Inc - Class A
NASDAQ: IRWD
$1.54
+$0.05 (+3.4%)
Closing Price on March 17, 2025
IRWD Stock Chart and Intraday Price
IRWD Stock Data
| Asset Type | Stock |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | LIFE SCIENCES |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Address | 301 BINNEY STREET, CAMBRIDGE, MA, US |
| Fiscal Year End | December |
| Latest Quarter | 12/31/2023 |
| Market Cap | 1,418.94M USD |
| Shares Outstanding | 156,529,000 |
IRWD Articles
If you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t ring a bell. Denner is the CEO and CIO of Sarissa Capital Management, a Greenwich-based...
Published:
Tuesday's top analyst upgrades and downgrades included Broadcom, Ciena, Deere, FedEx, IMAX, Ironwood Pharmaceuticals, Lululemon Athletica, LyondellBasell Industries, Nvidia and Starbucks.
Published:
The top analyst upgrades, downgrades and initiations seen for Monday included Allscripts Healthcare Solutions, AmeriGas Partners, CVS Health, IMAX, Kraft Heinz, Marathon Oil, Microsoft and Pfizer.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Wednesday included AIG, Freeport-McMoRan, Frontier Communications, Noble Energy, Occidental Petroleum, Spark Therapeutics and Target.
Published:
Last Updated:
Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming year.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday include AECOM, Ciena, Evoqua Water Tech, Funko, GlaxoSmithKline and Square.
Published:
Last Updated:
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares remained relatively muted on Monday after the firm announced a key U.S. Food and Drug Administration (FDA) approval for its gout treatment...
Published:
Last Updated:
After a couple of down years in which the shrill political rhetoric over drug prices kept a pall over the industry, biotech stocks are showing some signs of life.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include Anadarko, Apple, Charter Communications, FireEye, First Solar and Frontier Communications.
Published:
Last Updated:
Wednesday's top analyst upgrades, downgrades and initiations include Alphabet, Apple, Duke Energy, Kellogg, NVIDIA and Wells Fargo.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Monday, March 21, include AK Steel, Intel, Symantec, Tesla, US Steel and Valeant Pharmaceuticals.
Published:
Last Updated:
These are the top analyst upgrades and downgrades covered by 24/7 Wall St. on Thursday, September 4, 2014.
Published:
24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in hand, while others have pending FDA approval verdicts.
Published:
In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016 and 2017 numbers. Here are the top biotech names rated Outperform at Credit Suisse.
Published:
ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive on large cap biotechnology names. Acknowledging in their...
Published:
Last Updated:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.